Benign epithelial ovarian tumours - Cancer precursors or markers for ovarian cancer risk?

Cancer Causes and Control

Volumn 17, Issue 5, 2006, Pages 623-632

  Jordan, Susan ^a,b   Green, Adèle ^a   Webb, Penelope ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Benign ovarian tumours; Epithelial ovarian cancer; Malignant progression

Indexed keywords

BIOCHEMICAL MARKER; TUMOR MARKER;

BENIGN TUMOR; CANCER GRADING; CANCER INVASION; CANCER RISK; CANCER SCREENING; DISEASE COURSE; EPITHELIUM TUMOR; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; MUCINOUS CARCINOMA; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST;

DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 33646340671     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-005-0370-y     Document Type: Review

References (63)

1. Purdie D, Webb PM, Siskind V, Bain C, Green A (2003) The different etiologies of mucinous and non-mucinous epithelial ovarian cancers. Gynecol Oncol 88(1 Pt 2):s145-s148
2. Risch H, Marrett L, Jain M, Howe G (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144(4):363-372
3. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC-Press, Lyon
4. Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC, Lyon. Report No.: cancerbase No. 5
5. Russell P (1979) The pathological assessment of ovarian neoplasms. 1: Introduction to the common 'epithelial' tumours and analysis of benign 'epithelial' tumours. Pathology 11:5-26
6. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA (1989) Relative frequency of primary ovarian neolpasms: a 10-year review. Obstet Gynecol 74(6):921-927
7. Crayford T, Campbell S, Bourne T, Rawson H, Collins W (2000) Benign ovarian cysts and ovarian cancer: a cohort study with implications for screening. Lancet 355:1060-1063
8. Jacobs IJ, Menon U (2004) Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3(4):355-366
9. Russell P (1994) Surface Epithelial-Stromal tumors of the ovary. In: Kurman RJ (eds) Blaustein's pathology of the female genital tract. Springer-Verlag, New York, pp 705-782
10. Ness RB (2003) Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol 189(1):280-294
11. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23(1):41-44
12. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN (2003) Pathology and classification of ovarian tumors. Cancer 97(10 Suppl):2631-2642
13. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136(10):1184-1203
14. Hankinson S, Colditz G, Hunter D, Willett W, Stampfer M, Rosner B et al. (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2):284-290
15. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M et al. (1997) Tubal sterilisation, Hysterectomy, and decreased risk of ovarian cancer. Int J Cancer 71:948-951
16. Modugno F, Ness RB, Wheeler J (2001) Reproductive risk factors for epithelial ovarian cancer according to histological type and invasiveness. Ann Epidemiol 11:568-574
17. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM et al. (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83(3):575-585
18. Purdie D, Siskind V, Bain C, Webb PM, Green A (2001) Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 153(9):860-864
19. Riman T, Dickman P, Nilsson S, Correia N, Nordlinder H, Magnusson C et al. (2002) Risk factors for Invasive Epithelial Ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363-373
20. Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN et al. (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629-638
21. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D (1987) Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 294:1518-1520
22. Booth M, Beral V, Maconochie N, Carpenter L, Scott C (1992) A case-control study of benign ovarian tumours. J Epidemiol Commun Health 46:528-531
23. Parazzini F, Moroni S, Negri E, La Vecchia C, Mezzopane R, Crosignani PG (1996) Risk factors for seromucinous benign ovarian cysts in northern Italy. J Epidemiol Commun Health 51:449-452
24. Westhoff C, Britton J, Gammon M, Wright T, Kelsey J, (2000) Oral contraceptives and benign ovarian tumors. Am J Epidemiol 152:242-246
25. Britton J, Westoff C, Howe G, Gammon M (2000) Diet and benign ovarian tumors. Cancer Causes Control 11:389-401
26. Britton JA, Westhoff C, Howe GR, Gammon MD (2000) Lactose and benign ovarian tumours in a case-control study. Br J Cancer 83(11):1552-1555
27. Bourne T, Whitehead MI, Campbell S, Royston P, Bhan V, Collins WP (1991) Ultrasound screening for familial ovarian cancer. Gynecol Oncol 43:92-97
28. Bhan V, Amso N, Whitehead M, Campbell S, Roynton P, Collins W (1989) Characteristics of persistant ovarian masses in asymptomatic women. Br J Obstet Gynaecol 96:1384-1391
29. Pharoah P, Ponder BA (2002) The genetics of ovarian cancer. Best Pract Res - Clin Obstet Gynaecol 16(4):449-468
30. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700-710
31. Menkiszak J, Brzosko M, Gorski B, Flicinski J, Jakubowska A, Zebielowicz D et al. (2004) Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. J Appl Genet 45(2):255-263
32. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ et al. (2002) Infertility, fertility drugs and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 155(3):217-224
33. Dal Maso L, Canzonieri V, Talamini R, Franceschi S, La Vecchia C (2001) Origin of ovarian cancer from benign cysts. Eur J Can Prev 10:197-199
34. Shu XO, Brinton LA, Gao YT, Yuan JM (1989) Population-based case-control study of ovarian cancer in Shanghai. Cancer Res 49(13):3670-3674
35. Parazzini F, Moroni S, La Vecchia C, Negri E, dal Pino D, Bolis G (1997) Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 33(10):1634-1637
36. Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83(4):395-400
37. Swerdlow AJ, Green A (1987) Melanocytic naevi and melanoma: an epidemiological perspective. Br J Dermatol 117(2):137-146
38. Grulich AE, Bataille V, Swerdlow AJ, Newton-Bishop JA, Cuzick J, Hersey P et al. (1996) Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 67(4):485-491
39. Webb PM, Byrne C, Schnitt SJ, Connolly JL, Jacobs T, Peiro G et al. (2002) Family history of breast cancer, age and benign breast disease. Int J Cancer 100(3):375-378
40. Horiuchi A, Itoh K, Shimizu M, Nakai I, Yamazaki T, Kimura K et al (2003) Towards understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol;88:309-317
41. Stenback F (1981) Benign, borderline and malignant serous cystadenomas of the ovary. A transmission and scanning electron microscopical study. Path Res Practice 172:58-72
42. Gramlich T, Austin R, Lutz M (1990) Histological sampling requirements in ovarian carcinoma: a review of 51 tumours. Gynecol Oncol 38:249-256
43. Puls L, Powell D, DePriest P, Gallion H, Hunter J, Kryscio R et al. (1992) Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 47(1):53-57
44. Scully RE (1995) Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet 49(suppl):S9-S15
45. Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, Kurman RJ et al. (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484-486
46. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM et al. (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496-504
47. Bell DA, Scully RE (1994) Early de novo ovarian carcinoma. Cancer 73(7):1859-1864
48. Marshall R (1993) Benign to malignant transformation in epithelial ovarian tumours - letter. Hum Pathol 24(5):562
49. Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L (1993) Histologically benign or low-grade malignant tumours adjacent to high-grade carcinomas contain molecular characteristics of high grade carcinomas. Cancer Res 53:4138-4142
50. Zheng J, Benedict WF, Xu H-J, Hu S-X, Kim TM, Velicescu M et al. (1995) Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Ins 87(15):1146-1153
51. Kuwata T, Kitagawa M, Takemura T, Hirokawa K (1995) Proliferative activity and p 53 over-expression of ovarian epithelial tumours. Gen Diag Pathol 141(2):131-139
52. Wolf NG, Abdul-Karim FW, Schork NJ, Schwartz S (1996) Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential and fully malignant components. Am J Pathol 149(2):511-520
53. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J (1997) k-ras mutations in mucinous ovarian tumours. Cancer 79(8):1581-1586
54. Mandai M, Konishi I, Kuroda H, Kaomatsu T, Yamamoto S et al. (1998) Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 28(1):34-40
55. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC (2001) k-ras mutations may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 20:244-251
56. Shelling AN, Cooke IE, Ganesan TS (1995) The genetic analysis of ovarian cancer. Br J Cancer 72:521-527
57. Wenham R, Lancaster J, Berchuck A (2002) Molecular aspects of ovarian cancer. Best Practice and Research - Clin Obstet Gynaecol 16(4):483-497
58. Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4):1223-1228
59. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R et al (2004) In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202(3):336-340
60. Cheng EJ, Kurman RJ, Wang M, Oldt R, Wang BG, Berman DM et al. (2004) Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 84(6):778-784
61. Russell SE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203(2):617-619
62. Shih Ie M, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5):1511-1518
63. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767